225 related articles for article (PubMed ID: 37001720)
1. Cardiovascular Disease Risk and Statin Use Among Adults with Metabolic Dysfunction Associated Fatty Liver Disease.
Yeoh A; Cheung R; Ahmed A; Chitnis AS; Do A; Wong RJ
Am J Med; 2023 Jul; 136(7):669-676.e1. PubMed ID: 37001720
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020.
Jacobs JA; Addo DK; Zheutlin AR; Derington CG; Essien UR; Navar AM; Hernandez I; Lloyd-Jones DM; King JB; Rao S; Herrick JS; Bress AP; Pandey A
JAMA Cardiol; 2023 May; 8(5):443-452. PubMed ID: 36947031
[TBL] [Abstract][Full Text] [Related]
3. Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease.
Han E; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Kim SU
Gut Liver; 2022 Sep; 16(5):786-797. PubMed ID: 35321955
[TBL] [Abstract][Full Text] [Related]
4. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014.
Fan W; Philip S; Granowitz C; Toth PP; Wong ND
Diabetes Care; 2019 Dec; 42(12):2307-2314. PubMed ID: 31575639
[TBL] [Abstract][Full Text] [Related]
5. Age-based disparities in statin use for primary prevention in US adults: National Health and Nutrition Examination Surveys 2013-2020.
Zheutlin AR; Jacobs JA; Derington CG; Chaitoff A; Navar AM; Bress AP
J Clin Lipidol; 2023; 17(5):688-693. PubMed ID: 37599197
[TBL] [Abstract][Full Text] [Related]
6. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
[TBL] [Abstract][Full Text] [Related]
7. Statin Use in Older Adults for Primary Cardiovascular Disease Prevention Across a Spectrum of Cardiovascular Risk.
Sarraju A; Spencer-Bonilla G; Chung S; Gomez S; Li J; Heidenreich P; Palaniappan L; Rodriguez F
J Gen Intern Med; 2022 Aug; 37(11):2642-2649. PubMed ID: 34505981
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease.
Chun HS; Kim MN; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1168-1178. PubMed ID: 34337887
[TBL] [Abstract][Full Text] [Related]
9. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020.
Chobufo MD; Regner SR; Zeb I; Lacoste JL; Virani SS; Balla S
Eur J Prev Cardiol; 2022 Oct; 29(14):1830-1838. PubMed ID: 35653373
[TBL] [Abstract][Full Text] [Related]
10. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
[TBL] [Abstract][Full Text] [Related]
11. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease.
Rodriguez F; Maron DJ; Knowles JW; Virani SS; Lin S; Heidenreich PA
JAMA Cardiol; 2017 Jan; 2(1):47-54. PubMed ID: 27829091
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
13. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.
Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI
Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
Moon JH; Kim W; Koo BK; Cho NH;
Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
[TBL] [Abstract][Full Text] [Related]
15. Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older.
Orkaby AR; Driver JA; Ho YL; Lu B; Costa L; Honerlaw J; Galloway A; Vassy JL; Forman DE; Gaziano JM; Gagnon DR; Wilson PWF; Cho K; Djousse L
JAMA; 2020 Jul; 324(1):68-78. PubMed ID: 32633800
[TBL] [Abstract][Full Text] [Related]
16. Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study.
Yang Q; Zhong Y; Gillespie C; Merritt R; Bowman B; George MG; Flanders WD
BMJ Open; 2017 Jan; 7(1):e011684. PubMed ID: 28119384
[TBL] [Abstract][Full Text] [Related]
17. Projections of incident atherosclerotic cardiovascular disease and incident type 2 diabetes across evolving statin treatment guidelines and recommendations: A modelling study.
Engeda JC; Lhachimi SK; Rosamond WD; Lund JL; Keyserling TC; Safford MM; Colantonio LD; Muntner P; Avery CL
PLoS Med; 2020 Aug; 17(8):e1003280. PubMed ID: 32845900
[TBL] [Abstract][Full Text] [Related]
18. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey.
Fan W; Philip S; Granowitz C; Toth PP; Wong ND
J Clin Lipidol; 2019; 13(1):100-108. PubMed ID: 30594443
[TBL] [Abstract][Full Text] [Related]
19. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
[TBL] [Abstract][Full Text] [Related]
20. Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study.
van den Berg EH; Wolters AAB; Dullaart RPF; Moshage H; Zurakowski D; de Meijer VE; Blokzijl H
Liver Int; 2019 Jul; 39(7):1343-1354. PubMed ID: 30968536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
